Financials

  • Market Capitalization 3.79 M
  • Employee 21
  • Founded N/A
  • CEO N/A
  • Website www.aimimmuno.com
  • Headquarter Delaware, United States
  • FIGI BBG000JL6Z80
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.13
Price to sales ratio
20.76

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
5030
REVB
Revelation Biosciences, Inc. - Common Stock
1.01 USD+2.02%+1.00%-0.98%-26.81%3.95 M USD
5031
SXTP
60 Degrees Pharmaceuticals, Inc. - Common Stock
1.48 USD+2.07%-13.95%+3.50%-28.85%3.94 M USD
5038
GOVX
GeoVax Labs, Inc. - Common Stock
1.07 USD-3.60%-10.08%-14.40%-26.21%3.72 M USD
5054
GLMD
Galmed Pharmaceuticals Ltd. - Ordinary Shares
0.50 USD-7.41%-12.28%-21.88%-75.85%3.29 M USD

Frequently asked questions about AIM ImmunoTech Inc. Common Stock

What is the AIM ImmunoTech Inc. Common Stock stock price today?

The current price of AIM ImmunoTech Inc. Common Stock (AIM) is 0.26. Over the past 24 hours, the stock has changed by 0.00%. Follow the AIM chart for real-time price dynamics.

What is the stock ticker of AIM ImmunoTech Inc. Common Stock?

AIM ImmunoTech Inc. Common Stock trades under the ticker AIM. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is AIM ImmunoTech Inc. Common Stock stock going up?

AIM has changed by -13.33% over the last week, -39.53% over the last month, and -97.09% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was AIM ImmunoTech Inc. Common Stock net income for the last quarter?

AIM ImmunoTech Inc. Common Stock reported net income of -3.02 M for the last quarter. The previous quarter showed -4.17 M, which means net income changed by +27.59%.

How many employees does AIM ImmunoTech Inc. Common Stock have?

As of the latest available data, AIM ImmunoTech Inc. Common Stock has 21 employees. Workforce size can provide additional context about the company's scale and operations.

What is AIM ImmunoTech Inc. Common Stock EBITDA?

AIM ImmunoTech Inc. Common Stock EBITDA is -2.18 M, and its EBITDA margin is -9 922.73%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy AIM ImmunoTech Inc. Common Stock stock?

You can buy AIM ImmunoTech Inc. Common Stock (AIM) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in AIM ImmunoTech Inc. Common Stock stock?

Investing in AIM ImmunoTech Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AIM chart and related analysis on metatrader.com as part of your research.

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

News